HUTCHMED (China) Ltd (HCM): Long-Term Debt
$93.16M
As of 2025-12-31
+72.6%
3-year compound annual growth
+6.5%
10-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.16M | +12.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $82.81M | +4.4% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $79.34M | +338.3% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $18.10M | n/a | 2024-02-28, Balance as of period end |
| No annual figure between 2018-12-31 and 2022-12-31. | |||
| 2018-12-31 | $26.74M | -10.8% | 2019-03-11, Balance as of period end |
| 2017-12-31 | $29.99M | -35.9% | 2019-03-11, Balance as of period end |
| 2016-12-31 | $46.79M | -6.1% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $49.84M | n/a | 2017-03-13, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $93.16M | +12.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $2.01B | n/a |
| Insmed Inc (INSM) | 2025-12-31 | $546.77M | -51.3% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $343.97M | -21.3% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $372.19M | -36.4% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $202.83M | +34.5% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $589.70M | -15.8% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $494.86M | +31.7% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $108.96M | +1.6% |
Compare HCM, BBIO, INSM, OPK side by side · Screen every company in Pharmaceutical Preparations ↗